ClinicalTrials.Veeva

Menu

Time to Clearance of Chlamydia Trachomatis and Neisseria Gonorrhoeae RNA After Treatment: a Prospective Cohort Study (DECHLAGO)

U

University Hospital, Strasbourg, France

Status

Enrolling

Conditions

Uncomplicated Infections
Chlamydia Trachomatis
Neisseria Gonorrhoeae

Treatments

Diagnostic Test: Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) NAAT(s)

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The aim of this study is to evaluate the negativation time of chlamydial and gonococcal PCRs after treatment for urogenital, oropharyngeal and anal infections.

Enrollment

140 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

    • Patients attending the Trait d'Union department at the Nouvel Hôpital Civil for PrEP consultations, AES or HIV infection.
  • Over 18 years of age
  • Male or female
  • Who have had an uncomplicated CT and/or NG infection treated with currently recommended therapies (Ceftriaxone 500mg DU for NG infections, Doxycycline 200mg per day for 1 week for rectal CT infections and Azithromycin 1g DU or Doxycycline 7 days for other CT infections).
  • Subject affiliated to a social health insurance scheme
  • Subject able to understand the aims and risks of the research and to give dated and signed informed consent

Exclusion criteria

    • Complicated CT and/or NG infections: epididymitis, prostatitis, upper genital infection, extra-genital involvement (keratoconjunctivitis, arthritis, skin involvement, Fiessinger-Leroy-reiter syndrome, Fitz-Hugh-Curtis syndrome).
  • Interfering treatments and associated diseases: Severe immunosuppression (HIV infection with CD4 less than 200/mm3, chemotherapy in the last 6 months, active haemopathy, congenital immune deficiency, immunosuppressive treatment including corticosteroid therapy for more than 4 weeks or organ transplant.
  • Impossibility of giving the subject informed information (subject in an emergency situation, difficulties in understanding the subject, etc.).
  • Subject under court protection
  • Subject under guardianship or curatorship

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Central trial contact

Axel Ursenbach, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems